Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProstaMedix PET-CT for Prostate Cancer Diagnosis
NCT02282137Phase 2Unknown
- Start
- May 2015
- Primary completion
- Dec 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in prostate cancer (PCa). Status: unknown.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02282137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282137.